Puma Biotech

Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for the treatment of cancer. The company is particularly known for its targeted therapies that aim to address specific types of tumors, primarily those that express certain genetic markers. Puma’s lead product, Neratinib, is designed to target HER2-positive breast cancer and has received regulatory approval in various markets. The company’s mission centers around improving the outcomes for patients with cancer through the development of next-generation therapies and exploring potential treatment combinations to enhance efficacy and minimize side effects.